Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft‐versus‐host disease by inhibiting T‐cell migration to the gastrointestinal tract

Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft‐versus‐host disease by inhibiting T‐cell migration to the gastrointestinal tract

Abstract Introduction Allogeneic hematopoietic stem cell transplantation (aHSCT) is a curative treatment for hematopoietic malignancies. Graft‐versus‐host disease (GVHD) is a major complication of aHSCT. After transplantation, the balance of immune conditions, such as proinflammatory cytokine level...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Yukie Tsubokura, Hideaki Yoshimura, Atsushi Satake, Yutaro Nasa, Ryohei Tsuji, Tomoki Ito, Shosaku Nomura
Materialtyp: Artikel
Språk:English
Publicerad: Wiley 2022-09-01
Serie:Immunity, Inflammation and Disease
Ämnen:
graft‐versus‐host disease
hematopoietic stem cell transplantation
lenalidomide
regulatory T cells
Länkar:https://doi.org/10.1002/iid3.688

Internet

https://doi.org/10.1002/iid3.688

Liknande verk